SAN DIEGO--(BUSINESS WIRE)--Speaking today at the 4th Immunotherapeutics & Immunomonitoring Conference in San Diego, Dr. Galit Rotman, Chief Scientist of Therapeutics at Compugen Ltd. (NASDAQ: CGEN), presented data demonstrating the therapeutic efficacy of CGEN-15001, CGEN-15021 and CGEN-15091 in animal models of multiple sclerosis (MS), and the therapeutic efficacy of CGEN-15001 and CGEN-15021 in animal models of rheumatoid arthritis (RA). CGEN-15001, CGEN-15021 and CGEN-15091 are predicted B7/CD28-like proteins discovered using Compugen’s Protein Family Members Discovery Platform.
